Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > Leadership

<< Previous

Bullboard Posts

Next >>

Post by AngelaLon Sep 07, 2021 11:24pm

356 Views

Post# 33823479

Leadership

It's a pity that more news hasn't been released recently but we should not forget the awesome team leading Claritas. All leading figures in nitric oxide science and biotech. Salzman, Enkhbaatar, Cuzzocrea - these are all titans in their space. This team has been limited up to now by a shortage of capital but it would seem that this too is being solved, with the receipt of an Australian rebate and now soon to be debt and equity financing. Let's have a little patience. Those who invest now will be well rewarded.

<< Previous

Bullboard Posts

Next >>

Cizzle Brands, Changing Consumer Habits in Consumables